Stocktoria
Rein Therapeutics, Inc. RNTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2017-06-29
Rein Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $11.0M | $14.2M | $4.0M | $18.0M | $17.0M | $11.2M | $17.7M | $18.4M | $14.2M | $10.3M |
| Operating income | -$50.6M | -$65.1M | -$16.3M | -$27.6M | -$26.6M | -$20.5M | -$30.0M | -$31.9M | -$23.0M | -$18.2M |
| Income tax | -$712,000 | -$1.5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$49.9M | -$62.9M | -$15.7M | -$27.3M | -$26.2M | -$27.3M | -$29.4M | -$31.5M | -$22.6M | -$18.1M |
| EPS (diluted) | $-1.96 | $-3.51 | $-3.42 | $-6.02 | $-5.89 | — | — | — | — | — |
| Operating cash flow | -$19.4M | -$22.3M | -$19.8M | -$24.9M | -$23.8M | -$20.5M | -$26.5M | -$27.9M | -$20.5M | -$15.0M |
| Free cash flow | — | — | — | — | -$23.9M | -$20.5M | -$26.6M | -$32.3M | -$20.7M | — |
| Cash & equivalents | $3.2M | $12.9M | $17.3M | $5.2M | $3.6M | $7.0M | $5.3M | $10.6M | $11.9M | $20.7M |
| Total assets | $24.2M | $62.2M | $106.0M | $22.0M | $48.5M | $16.3M | $26.5M | $30.3M | $52.7M | $22.0M |
| Total liabilities | $7.2M | $7.8M | $7.7M | $3.4M | $4.6M | $4.2M | $10.4M | $10.7M | $4.9M | $4.1M |
| Shareholders' equity | $16.9M | $54.4M | $98.3M | $18.6M | $43.9M | $12.2M | $16.0M | $19.6M | $47.8M | -$111.8M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.